Trial Profile
Oral CEF(Cyclophosphamide, Epirubicin, UFT) adjuvant chemotherapy for breast cancer with intra-patient dose escalation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Tegafur/uracil (Primary) ; Cyclophosphamide; Epirubicin
- Indications Breast cancer
- Focus Therapeutic Use
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 14 Jun 2013 Planned End Date changed from 1 Jun 2013 to 1 Aug 2013 as reported by University Hospital Medical Information Network - Japan.
- 08 Jun 2009 New trial record.